Get App
Download App Scanner
Scan to Download
Advertisement
This Article is From Jul 11, 2025

Religare, UPL, Maruti Suzuki, BLS International, Infosys, Wockhardt Are Buzzing On The Dealers' Desk

Religare, UPL, Maruti Suzuki, BLS International, Infosys, Wockhardt Are Buzzing On The Dealers' Desk
Heard On The Street provides readers with what well-informed investors, especially HNIs, FIIs, DIIs, and mutual funds, are buying and selling in the stock market. It also tracks the latest unconfirmed/unverified chatter around stocks and/or sectors. (Image source: Canva AI)

NDTV Profit India has been tracking the action in the top dealing rooms of India's financial capital, and this edition of ‘Heard On The Street' provides you with buzzing action on stocks like Religare, UPL, Maruti Suzuki, BLS International, Infosys and Wockhardt.

Heard On The Street provides readers with what well-informed investors, especially HNIs, FIIs, DIIs, and mutual funds, are buying and selling in the stock market. It also tracks the latest unconfirmed/unverified chatter around stocks and/or sectors.

NDTV Profit picked up the following cues from the dealing room chatter during trade:

Religare

The company's board will meet today to discuss fundraising. The buzz on the street is that the company might do a preferential issue to the Burman family of around Rs 1000 crore.

UPL

Dealers indicate that foreign institutional investors are showing buying interest at lower levels.

Maruti Suzuki

The stock is down in trade owing to the downgrade by UBS today. However, dealers indicate that there are buy flows on institutional desks at lower levels.

BLS International

Dealers indicate the high net worth individuals have been accumulating this counter in trade today on expectations of some positive development.

Infosys

Largely all IT stocks have declined in trade post weak numbers from TCS. But for Infosys, dealers indicate strong buying interest at lower levels.

Wockhardt

There are buy flows on large high-net-worth individual desks in anticipation of a good licensing deal post the Glenmark-AbbVie deal. As per dealers, even Wockhardt has a novel asset in phase III trials with best-in-class trial data.

Disclaimer: The mentioned stocks capture NDTV Profit's dealing room channel checks during trading hours. The information provided is for informational purposes. However, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, or suitability of the information. This content does not constitute financial, investment, or trading advice and should not be construed as a recommendation to buy, sell, or hold any securities.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search